We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I refuse

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistics

We use tools, such as Google Analytics, to track web traffic and verify the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Press Releases

Bioxodes raises EUR 7.65 million to cover its clinical Phase I study and to obtain first proofs of efficacy in patients

Bioxodes raises EUR 7.65 million to cover its clinical Phase I study and to obtain first proofs of efficacy in patients
Press Releases
Bioxodes raises EUR 7.65 million to cover its clinical Phase I study and to obtain first proofs of efficacy in patients

Marche-en-Famenne, Belgium, June 2019

Following a successful preclinical program completion demonstrating the efficacy and safety of its lead compound, Ir‑CPI, Bioxodes SA has completed a EUR 7.65 million capital increase. It was carried out among the current shareholders as well as new investors. A repayable advance of EUR 2.65 million was granted by the Walloon Region which has been actively supportive since the creation of the company. With this capital increase, Bioxodes SA wishes to demonstrate the safety of Ir-CPI in humans (Phase I) but also to obtain first proofs of efficacy in patients.